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Chronic kidney disease (CKD), prevalent in more the 10% of the United States 
population is a progressive, degenerative disease affecting the renal function of afflicted 
individuals. In recent decades CKD has gained awareness among clinicians and medical 
professional due to growing concern for the many complications that arise in patients with CKD. 
For providers, CKD patient populations pose a significant challenge in terms of quality treatment 
because of the many associated risk factors and co-morbidities associated with a CKD diagnosis. 
The KDIGO (Kidney Disease; Improving Global Outcomes) 2012 clinical guidelines for the 
treatment of CKD were published under the sponsorship of the National Kidney Foundation in 
order to create uniform measures aimed to improve quality care and effective treatment of the 
CKD population. The purpose of this study is to investigate the extent to which these measures 
are being implemented and adhered to among providers at the practice level. Analysis of 
adherence to six specific measures of the KDIGO guidelines offers insight into the areas of 
implementation strengths and weaknesses. Results of this study indicate a widespread variation 
in the level of adherence to each measure on the practice level as well as variation among 
individual providers to each measure. While adherence levels were high among providers for 
certain measures, high adherence was not uniform across all six measures. Results of this study 
indicate the potential for improvement in CKD treatment through the use of centralized 
implementation structures such as practice based research networks (PBRN) or practice 
facilitation in order to generate higher adherence to all six KDIGO measures.  
Introduction  
 Chronic kidney disease (CKD) is a serious condition affecting the renal function of 
afflicted individuals and is associated with progression of kidney failure, cardiovascular disease, 
and premature death (Levey et al., 2005). Kidney function can be assessed on the basis of an 
estimated glomerular filtration rate (eGFR), which estimates how much blood passes through 
glomeruli each minute (National Library of Medicine). Glomeruli are components of the kidney 
that function to filter waste out of blood. CKD can be diagnosed by two eGFR readings of less 
than 60 milliliters per minute (mL/min) taken more than ninety days apart (Kidney Disease: 
Improving Global Outcomes [KDIGO]). A diagnosis of CKD is further defined on the basis of 
the severity of decline in renal function. CKD is a progressive disease with five stages classified 
by specific eGFR ranges correlating to increasingly severe declines in renal function. Stages one 
and two are associated with the most mild loss of kidney function. Stage three, consisting of sub-
stages 3a and 3b, define moderate loss in kidney function with stage 3b, a eGFR of 44-30 
mL/min, considered moderate to severe loss of renal function. A stage four diagnosis is classified 
by an eGFR reading of 29-15 mL/min and severe loss of function while stage five reflects 
complete renal failure characterized by an eGFR less than 15 mL/min. A more severe CKD 
diagnosis carries with it greater risk factors for progression towards end stage renal disease and 
dialysis. According to estimates published by the Center for Disease Control (CDC) in 2014, 
more than 10% of the United States population, or 20 million individuals, have CKD. A recent 
national increase in the prevalence of major risk factors for CKD including obesity, 
hypertension, and type 2 diabetes has contributed to this large number of CKD cases (Fox et al., 
2013). Since CKD patients represent a population at increased risk for renal failure and dialysis, 
as well as other cardiovascular complications, they pose a number of challenges for providers in 
the delivery of care. Implementation of effective treatment plans for patients with CKD holds the 
potential for improving population health through the elimination of complex medical scenarios 
that arise with the progression of CKD and, ultimately, renal failure.  
Evidence based clinical studies have identified major risk factors associated with the 
progression of CKD, namely, cardiovascular disease (CVD), use of non-steroidal anti-
inflammatory drugs (NSAIDs), and type 2 diabetes. Control of these risk factors presents a target 
for clinical treatment that has the potential to slow the progression of CKD and reduce the 
number of CKD patients with severe renal failure. Patients with CKD have been found to be at 
high risk of developing severe CVD. In fact, CVD has become one of the leading causes of 
mortality in patients with CKD with 50% of all deaths in patients with end-stage renal disease 
being a result of CVD (Parikh et al., 2006). Similarly, individuals diagnosed with CKD are more 
likely to die from these accelerated CVD complications than to reach a stage 5 diagnosis of 
complete renal failure (Schiffrin et al., 2007). Risk factors associated with CVD are also 
extremely high in these patients with studies showing high prevalence rates of hypertension, 
abnormal lipids, and type 2 diabetes in the CKD patient population (Parikh et al., 2006). 
Previous studies have indicated that increased CVD risk among CKD patients is related to 
inadequate drug therapy because patients with limited renal function are less likely to receive 
cardio-protective medications that would otherwise reduce their CVD risk (Schiffrin et al., 
2007). In addition to an increased risk for the development of CVD and its associated factors, 
previous research has indicated a negative correlation between the use of NSAIDs and the 
progression of CKD. NSAIDs have been shown to have adverse acute effects on kidney function 
and account for 16% of all cases of drug related renal failure (Ingrasciotta et al., 2015).  Recent 
clinical studies have subsequently identified NSAID use as a contributing factor in chronic 
adverse renal effects and the progression of CKD (Ingrasciotta et al., 2015). NSAID drug activity 
leads to a decrease in renal blood flow, which poses a significant risk for progression of 
decreased renal function in patients with CKD (Plantinga et al., 2011). In fact, it has been 
demonstrated that the use of NSAIDs among a population having a baseline eGFR of 60 and 89 
mL/minute correlated with a significant increase in risk of progression of CKD (Gooch et al., 
2007).  
 In light of identification of these risk factors associated with the progression of CKD as 
well as its prevalence as a widespread chronic condition, the 2012 KDIGO clinical guidelines for 
the treatment of CKD were published under the sponsorship of the National Kidney Foundation. 
These international, evidence based guidelines were developed to create clinical measures aimed 
to improve care and outcomes for patients with CKD. Table 1 in Appendix A lists the six 2012 
KDIGO guideline measures that were the focus of this study. These include, measure one, proper 
documentation of CKD diagnosis; measure two, current prescription of an angiotensin-
converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB); measure three, 
discontinuation of NSAID medications; measure four, blood pressure reading less than 140/90; 
measure five, a lipid panel LDL reading less than 100; and measure six, a hemoglobin A1C 
reading lower than seven for all diabetic patients with CKD (KDIGO, 2013). Among these six 
guidelines, measures two, four, and five are aimed to specifically address the increased risk for 
ischemic heart disease and hypertensive heart disease present in the CKD patient population 
(KDIGO, 2013). These CVD specific guidelines were created on the basis of the assumption that 
all CKD patients are considered to be at increased risk for developing CVD (KDIGO, 2013). 
This assumption is based on clinical studies that indicate a 43% increase in risk of CVD 
symptoms among stage 3a CKD patients and a 343% increased CVD risk in stage five CKD 
patients (KDIGO, 2013). Accordingly, these specific blood pressure and LDL values reflect 
optimal targets providers should aim for in their CKD patient population in order to better 
control CVD risk. Administration of ACE inhibitors or ARB’s which are used to manage systolic 
heart failure also reflect this measure of preventative CVD care among CKD patients suggested 
in the KDGIO guidelines. In addition, the KDIGO included measure six as an aim towards 
improved control of type 2 diabetes in patients in CKD (KDIGO, 2013) This recommendation 
specifically addresses the risk of micro-vascular complications associated with uncontrolled 
diabetes to which CKD patients are more susceptible. Measure three addresses the increasingly 
problematic use of NSAIDs among CKD patients who often experience other co-morbidities 
such as hypertension or chronic arthritis. This particular measure aims to address the concern of 
NSAID use among CKD patients by setting dosage guidelines that allow for the continuation of 
NSAID pain management treatment while also protecting CKD patients from the adverse effects 
of these medications. These above recommendations listed in Table 1 were identified as the 
specific measures from the KDIGO publication that will be the focus of this study, which will 
analyze provider adherence to these clinically based guidelines.  
Specific Aims  
Since the publication of these guidelines, little research has been conducted to determine 
how well physicians are adhering to these clinical measures. Addressing this question could 
improve patient care and, subsequently, population health by improving clinical treatment at the 
provider level. The primary goal of this project is to examine the extent to which clinicians in a 
family medicine practice located in an urban community are following six major clinical 
measure as presented in the 2012 KDIGO guidelines. The secondary goal of this project is to 
discover the level of variation that exists among adherence to each of these measures.  
Specific Aim One:  
To determine the number measures this practice and its individual providers are adhering 
to in the treatment of at least 50% of their CKD patient population.   
Specific Aim Two:  
To determine the variation in percentage of patients treated appropriately for each 
measure on a practice and provider level. This will assess the level of variation in quality 
care within the practice.  
Specific Aim Three:  
To use analysis of this data to determine areas of strength and weakness in terms of 
accordance to specific guideline measures.  
These specific aims will aid in my examination of adherence to KDIGO clinical guidelines as a 
means of quality improvement and improved patient outcomes.  
Methods 
In the present study, my methodology will consist primarily of a review of 835 patient 
charts using the Allscripts electronic medical records system. The 835 patients included in this 
data set and identified as subjects of this study are all individuals from a single family medicine 
practice located in an urban community. Each of these patients has had at least one recorded 
eGFR reading less than 60 mL/min. A single eGFR reading less than 60 mL/min identifies the 
possibility of a CKD diagnosis. A second eGFR reading less than 60 mL/min more than 90 days 
after the first reading confirms this diagnosis. The purpose of this chart review will be to first 
determine, for each of the 835 patients, whether or not the patient has a diagnosis of CKD, as 
indicated by a second eGFR reading less than 60 mL/min taken at least 90 days after the initial 
reading. Once CKD patients have been identified from this set of 835 individuals, further chart 
review will be used to determine how well the primary care provider for each CKD patient is 
following the six specific KDIGO measures previously discussed.  
Adherence to measure one, proper documentation of CKD diagnosis, is met if a CKD 
diagnosis appears in the patient’s medical record. Measure two, prescription of ACE inhibitors or 
ARB medications, is met if a medication of either one of these categories is listed as an active 
prescription on the patient medication list. Adherence to measure three, non-prescription or 
discontinuation of NSAID medication, is met if all medications that act as NSAIDs do not appear 
on the active patient medication list. Aspirin, for the purposes of this study and in accordance to 
the KDIGO guidelines, is not considered to have adverse effects on CKD patients when 
prescribed up to 81 mg. Adherence to measure three, therefore, will still be met in the presence 
of an active aspirin prescription on the medication list as long as it’s dosage does not surpass 
81mg. Measure four, a blood pressure reading less than or equal to 140/90, will be met if the 
most recent blood pressure reading in the patient’s chart is less than or equal to this value. 
Measure five, an LDL less than or equal to 100, will be met if the lipid panel results from the 
most recent blood testing present in the patient’s cart is less than or equal to this value. Finally, 
adherence to measure six, a hemoglobin A1C (HbA1C) less than or equal to seven for diabetic 
patients, will be met if the most recent HbA1C reading present in the chart of a CKD patient, 
who has been identified as a diabetic, is less than or equal to seven. This chart review process 
will be conducted for each individual of the data set of 835 who are identified as CKD patients. 
During this review process the primary care provider for each CKD patient will be identified. 
This information allow the final set of a accumulated data to be analyzed on a provider by 
provider level in addition to an overall practice level analysis.  
Once this chart review has been completed, adherence to each measure will be scored on 
a scaled system to identify low, moderate, and high adherence on a practice level basis. These 
scores will be given based on the percentage of cases, out of the total CKD patients in this 
practice, that are being treated appropriately for each of the six measures. Percentage values from 
0-33.3% will be categorized as low adherence, percentage values from 33.4-66.6% will be 
categorized as moderate adherence, and percentage values from 66.7-99.9% will be categorized 
as high adherence. According to these graded levels of adherence I will identify the measures to 
which the practice is performing the best in terms of adherence to guidelines as well as those 
measures the practice is adhering to less optimally.  
After scoring measures on the basis of low, moderate, and high adherence on the practice 
level, individual provider performance will be assessed by comparing each provider’s results to 
the average practice percentages for each measure. Adherence to guidelines will again be 
measured by calculating the percentage of CKD patients, treated by a particular provider, of the 
total number of CKD patients the provider treats who are receiving the appropriate treatment for 
each measure. These percentages will be graded ‘above’ or ‘below’ average by comparing each 
with the practice level percentages determined in the first phase of analysis. These above and 
below grades will be further characterized on the basis of deviation from the practice level 
average. These comparative results will indicate the spread in level of adherence to guidelines 
that exists among providers for each measure. This will aid in determining the level to which 
consistency in adherence to specific guidelines exists among providers in this practice.  
Through this gathering of data via chart review and the analysis of these results this study 
hopes to reveal areas of strengths and weaknesses in terms of clinical adherence to KDIGO 
guidelines three years after their initial publication. These results will serve as a basis from 
which new methods of quality improvement may emerge to better implement those measures 
that are not being followed as well as others.  
Results  
 After conducting the chart review, 291 of the 835 patients from the original data set were 
identified as having CKD. At the practice level, adherence to guideline recommendations in at 
least 50% of the CKD patient population was met for five of the six measures analyzed as shown 
in Table 2. At the practice level, 229 or 78.70% of these patients had appropriate documentation 
of CKD diagnosis on their problem list, giving measure one a score of high adherence. Measure 
two received a score of moderate adherence as only 53.20% or 152 total CKD patients were 
prescribed ACE inhibitors or ARB’s. Measure three was given a score of high adherence with 
241 patients, 82.80%, currently not taking NSAIDs. Measure four received a practice level score 
of high adherence as 79.70%, or 231 of the 290 patients with documented blood pressure 
readings available, were at goal of less than or equal to 140/90. The one CKD patient without a 
documented blood pressure reading available was not considered for this measure. A moderate 
adherence score was given to measure five as only 143 of the 264 CKD patients with 
documented blood tests available, 53.40%, had LDL equal to or below 100. The 23 patients who 
did not have blood test labs available were not considered for the measure. Of the 153 total 
diabetic CKD patients in this study, only 152 had documented HbA1c measurements available 
for analysis. Of these 152 patients, only 68 or 44.74% were at goal of equal to or less than seven.  
Accordingly, measure six received a moderate adherence score as well. This was the only 
measure, on the practice level, of the six in which appropriate adherence was not met in the 
treatment of at least 50% of CKD patients. Overall, the practice received moderate adherence 
scores for three measures, high adherence scores for three measures, and received no low 
adherence scores.  
 Eight individual providers were identified during the chart review as primary care 
physicians for 258 of the CKD patients. There were 33 patients without a specific primary care 
physician listed in their chart. These patients were placed collectively in the ‘unknown 
physician’ category for purposes of carrying out a provider level analysis. This category is 
designated as provider nine in the data analysis. The average adherence percentages for each 
measure for these nine providers were; measure one, 77.31%; measure two, 51.23%; measure 
three, 86.67%; measure four, 79.49%; measure five, 52.97%; and measure six, 41.13% (Table 4). 
These averages can be further categorized as high adherence for measures one, three, and four 
and moderate adherence for measures two five and six. These averages align closely with the 
results obtained for practice level adherence and provide average achievement levels to which 
performance of each individual provider can be compared and measured. Table 3 indicates both 
the total number of CKD patients and the number of diabetic CKD patients treated by each of the 
nine providers. These values were used to calculate the adherence levels for each of the nine 
providers based on the specific patient population each treated. Each provider’s percentage level 
adherence to each of the six measures was compared to the average adherence percentages found 
in Table 4. These comparisons are shown in Table 5, which illustrates the difference in 
percentage values between each individual provider and the provider averages for each measure. 
Each difference was categorized as below or above average performance indicated by negative 
and positive values, respectively. According to these results it was determined that above 
average performance was seen in five providers for measures one, two, four, and six. Above 
average performance was seen among six providers for measures three and five. None of the 
providers achieved above average performance in all six measures nor did any provider receive 
below average scores for all six measures.  
 Also presented in Table 5 is the variation in level of adherence among the nine providers 
as well as among the six measures for each individual provider. These results indicate a 
significantly large variation among providers in adherence levels for each of the six measures 
when compared to the practice average percentages. Table 5 also displays the significant 
variation in individual adherence levels to the six measures. As illustrated, the extent to which 
each individual provider performed above or below the practice average for each of the six 
measures varied substantially. None of the nine providers were found to have either above 
average or below average performance for all six measures. Instead, adherence levels varied for 
each provider depending on the specific measure being assessed. Variation in adherence among 
measures for each individual provider are evident throughout the results of this study and 
indicate the possibility of an inconsistency in the overall implementation of each of these six 
KDIGO measures among providers within practices.  
Discussion  
 The findings of this study provide important information regarding current clinical 
treatment of CKD. Based upon the findings of this study several conclusions can be drawn 
regarding the level of adherence to KDIGO clinical based guidelines. On the practice level, 
adherence to guidelines in at least 50% of the CKD patient population was met for five out of six 
measures. Of these five, practice adherence to three measures- one, three, and four- was greater 
than 75% with the greatest percentage of overall practice adherence being for measure three, 
patients with CKD not being prescribed NSAIDs. These high levels of adherence to measures 
three and four both of which are address CVD risks associated with CKD suggest an elevated 
level of provider awareness to CVD risks in this patient population. Although measures two, 
five, and six received moderate rather than high adherence scores, these values were still above 
the low adherence threshold. While these values indicate significant room for improvement, it is 
also clear that implementation and attention to these recent guidelines are not falling in the 
lowest range adherence. These results offer and important justification of the KDGIO measures 
as guidelines that are readily applicable at the practice level clinical treatment of CKD.  
The extent of variation in adherence among specific measures and providers was another 
important finding garnered from this study. Although, as indicated above, there are areas of high 
performance on the practice level in terms of implementation of certain measures, the variation 
in level of adherence that exists among providers suggests a weakness in the implementation of 
KDIGO guidelines. As shown in Table 6, for each measure, variation in adherence to guidelines 
spans a range of at least 26.1 percentage units. In the case of four of the measures, the range of 
values is greater than 30 units. This widespread variation in adherence found for each measure 
indicates that while performance for a particular measure may be high for one individual 
provider, this high performance is not maintained evenly throughout the practice. Rather, there is 
a large divide among providers in a single practice in terms of level of adherence to these 
guidelines. This finding reveals a larger implication regarding clinical care, namely, that 
treatment of CKD is not consistent within a single practice.  
This inconsistency is also illustrated in the variation of individual provider adherence to 
each of the six measures. None of the nine providers had above average performance for all six 
measures. Even more surprisingly, however, was the deviation in each provider’s performance 
levels for the six measures. Although these ranges were significantly smaller than those found 
when comparing all nine providers to one another, the discrepancy in adherence for the same 
provider to different measures indicates another level of weakness in the implementation of 
KDIGO guidelines. While an individual provider may be aware and attentive to one or a few of 
the major KDIGO guidelines, these findings indicate that providers are not consistently adhering 
to all six measures equally. Since each of these six measures were designed by the KDIGO 
guidelines to bring about the greatest level of quality care for CKD patients, implementation of 
these measures should be uniform throughout individual provider care as well as on the practice 
level as a whole. This study, therefore reveals important information by revealing areas of 
strength in guideline implementation as well as areas of weakness that are in need of 
improvement.  
 Before highlighting specific areas of weakness and tools necessary to improve 
implementation of these measures it is important to note the areas of success revealed by the 
findings of this study. As previously noted measures one, three, and four all received high 
adherence scores on the practice level as well as in terms of average adherence percentages. 
These results indicate that there are areas of high performance in providing quality care in the 
treatment of CKD for a large proportion of this patient population. These successes also suggest 
that the measures created by the KDIGO guidelines are, in fact, applicable and translatable to the 
everyday setting of the clinical practice.  
While these successes are important to note and provide support for the legitimacy of 
implementing guideline standards into clinical care, the weaknesses of implementation, 
illustrated by low adherence values and high variability among provider adherence to each 
measure, are significant findings that provide important information as well. Moderate adherence 
levels for measures two, five and six provide evidence for the need to improve implementation 
efforts of these guidelines at the practice level. Providing the best quality of care requires 
adherence to all of the KDIGO measures rather than a select few. Therefore measures must be 
taken to improve adherence levels across the board. Provider awareness of these particular 
guidelines and measures is essential in the implementation of appropriate treatment. Recent 
studies have indicated the success of practice based research networks (PBRNs) in creating 
practice environments where implementation of more effective and efficient quality care is better 
achieved (Mold et al., 2014). The structure of PBRNs, which allow for communication between 
academic researchers providing practice performance feedback, practice facilitators (PFs), and 
practice clinicians and staff, creates a practice environment better equipped to implement new 
measures of quality care (Mold et al., 2014). According to the findings of this study, the use of 
centralized intervention programing such as the PBRN model accelerates the implementation of 
clinical measures and guidelines. Moving forward, the use of PBRNs in conjunction with 
practice facilitation has the potential to improve the CKD guideline implementation process by 
better assuring that each provider becomes more well equipped to address all six measures of the 
KDIGO guidelines. Through this facilitation, one could reasonably expect a drop in variation 
among providers’ adherence levels due to increased practice-wide awareness of each CKD 
treatment measure. Additionally, moving forward, more publications supporting the efficacy of 
these particular measures in improving CKD patient health would generate more widespread 
attention and subsequent adherence to these guidelines thereby increasing performance levels.  
Limitations and Suggestions  
 This study is not without limitations and constraints. Since this study was restricted to a 
single practice of providers serving a particular demographic of the CKD population it’s results 
are limited and reflective only of a single practice. Expanding this study to include a larger 
sample of practices from a variety of different regions has the potential extend this analysis to a 
greater population of the providers, which could lead to significant results. Additionally, given 
the results gathered from this study, further designs could be established to evaluate the 
effectiveness of PBRN implementation programs aimed to generate greater adherence. An 
ancillary study that re-evaluates adherence levels in this practice post practice-facilitation efforts 
to better implement guideline measures could determine how successful such facilitation is based 

















Appendix A  
Identification of KDIGO Measures  
Measure 1 Appropriate documentation of CKD diagnosis 
on patient problem list  
Measure 2 Prescription of ACE inhibitor or ABR  
medication  
Measure 3 Patient not prescribed NSAID medications  
Measure 4 Blood pressure less than or equal to 140/90  
Measure 5 LDL less than or equal to 100  
Measure 6 HbA1c less than or equal to 7 for CKD patients 
with diabetes  
 
Table 1: Description of each of the six specific KDIGO measures analyzed in this study.  
 
   Practice Level Adherence to Guidelines  
Measure  Percentage  Adherence Score 
1 78.70% High 
2 53.20% Moderate 
3 82.80%, High 
4 79.70% High 
5 53.40%, Moderate 
6 44.07% Moderate 
 
Table 2 : Practice adherence to each of the six KDGIO measures represented as percentage of 














Provider Total Number of CKD 
Patients 
Total Number of CKD 
Patients with Diabetes 
1 44 19 
2 47 28 
3 46 26 
4 41 27 
5 8 5 
6 2 0 
7 63 30 
8 7 2 
9 33 16 
Totals:  291 153 
 
Table 3: Number of CKD patients treated by each primary care physician in this practice as well 
as the number of those patients who have also been diagnosed with diabetes. 
 
    Average Adherence Percentages 
Measure  Percentage  Adherence Score 
1 77.31% High  
2 51.23% Moderate 
3 86.67% High  
4 79.49% High  
5 52.97% Moderate  
6 41.13% Moderate 
 
Table 4: Average provider adherence to guideline percentages for each of the six measures and 





Individual Provider Deviation from Average Adherence Percentages 
Provider Measure 1 Measure 2 Measure 3 Measure 4 Measure 5 Measure 6 
1 -1.40% 11.40% 8.10% -0.20% 0.40% 2.70% 
2 10.60% -13.90% -1.90% 5.40% -2.20% -19.70% 
3 14.80% -8.70% -8.90% 0.70% 5.70% 9.10% 
4 9.10% 8.78% -12.10% 5.70% 7.10% -0.30% 
5 -3.70% -14.70% 4.70% -4.70% 6.60% -4.70% 
6 -28.70% -2.20% 17.20% 20.30% -3.40% N/A 
7 -26.30% 3.40% 4.50% 4.40% 4.00% 8.60% 
8 7.00% 4.90% 17.20% -8.30% 3.70% 5.30% 
9 6.10% 2.30% 5.10% -25.20% -25.80% 11.60% 
 
Table 5: Difference in percentage adherence values among providers for each measure as 
compared to the provider average adherence values. Green shading indicates above average 
performance and red shading indicates below average performance. Shows only difference in 
adherence percentages between provider and average values; not indicative of actual adherence 












Range of Adherence Percentages Among Providers   
Measure 1 43.5 
Measure 2 26.1 
Measure 3 29.3 
Measure 4 45.5 
Measure 5 32.9 
Measure 6 31.3 
 
Table 6: Range values of provider adherence percentages for each of the six measures. These 
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